A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

The U.S. Department of Agriculture has given a conditional approval to Zoetis to use its bird flu vaccine in poultry, the ...

Texas Attorney General Ken Paxton has launched an investigation into DeepSeek, the upstart Chinese artificial intelligence ...

Is street cleaning suspended for Presidents' Day weekend in Hoboken? What about parking rules? What's closed? Get the updates ...

The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Super Micro Computer rises sharply, Nvidia sells its stake in SoundHound, Airbnb swings to a profit in the fourth quarter, and Moderna posts a wider-than-expected quarterly loss.

The S&P 500 closed just shy of record Friday as data pointing to weakness in the consumer and ongoing inflation concerns weighed upside momentum. At 4:00 p.m. ET ...

GameStop wants to be more like MicroStrategy —and those plans are boosting the stock Friday. According to CNBC, which cited ...